Increased serum levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized healthy donors with G-CSF: a cohort study

Joan Cid,Katia Guinetti-Ortiz,Paola Charry,Gloria Carbassé,Mar de Pablo-Miró,Laura Rubia,Marta Garcia,Jose Alcaraz-Quiles,Enric Cascos,Nuria Martínez-Cibrian,María Queralt Salas,Maria Suárez-Lledó,Laura Rosiñol,Francesc Fernández-Avilés,Carmen Martínez,Montserrat Rovira,Miquel Lozano
DOI: https://doi.org/10.1016/j.tmrv.2024.150824
IF: 6.969
2024-03-17
Transfusion Medicine Reviews
Abstract:Limited data regarding elevation of N-terminal pro-B-type natriuretic peptide (NT-proBNP) in mobilized donors with G-CSF is available. We extended these findings by examining serum NT-proBNP in a cohort study including 35 healthy donors and 69 patients who received G-CSF for CD34+ mobilization as well as 54 patients who did not receive G-CSF but who underwent collection of CD3+ cells for chimeric antigen receptor (CAR) T-cell manufacturing. No donor in the three cohorts experienced significant cardiac adverse events. NT-proBNP levels were measured before and after G-CSF administration and after finishing apheresis procedure. NT-proBNP increase was observed in mobilized healthy donors after G-CSF administration, but was not observed in mobilized or non-mobilized patients. Only in the cohort of healthy donors, pairwise comparisons using Wilcoxon signed ranks test showed a significant increase between the mean serum NT-proBNP level after G-CSF administration and the mean serum NT-proBNP level measured before G-CSF administration (231.09±156.15 pg/mL vs. 58.88±26.84 pg/mL; p<0.01). No correlation was observed between NT-proBNP increase and G-CSF dose (r s =0.09; n=32; p=0.6) and no other variables contributing to predict serum NT-proBNP increase were detected. In conclusion, we observed a statistically, although not clinically, significant increase of NT-proBNP in healthy donors who received G-CSF as CD34+ cell mobilization.
hematology
What problem does this paper attempt to address?